Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium bifidum A218
- Development stage
- Unknown
- Lead developer
- Athelas
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium bifidum A218 is a specific strain of probiotic bacteria being developed as a live biotherapeutic product (LBP) for the treatment of inflammatory and allergic conditions, most notably atopic dermatitis. Developed by the South Korean biotechnology company Athelas, A218 functions by modulating the host's immune response through the induction of regulatory T cells (Tregs) and the stimulation of anti-inflammatory cytokines such as interleukin-10 (IL-10). This immunomodulatory action helps to suppress the Th2-biased immune response characteristic of allergic diseases, leading to a reduction in serum immunoglobulin E (IgE) levels and improvement in clinical symptoms. The strain is administered orally and has been evaluated in Phase 1/2 clinical trials to assess its safety and efficacy in patients with atopic dermatitis, representing a novel microbial approach to managing chronic inflammatory skin disorders.
- Other names
- B. bifidum A218
02
Targets
IL10 (Interleukin-10)TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on bifidobacterium bifidum A218.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium bifidum A218.